Harvoni (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
254 | Porphyria | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03118674 (ClinicalTrials.gov) | September 6, 2017 | 13/4/2017 | Harvoni Treatment Porphyria Cutanea Tarda | Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C | Porphyria Cutanea Tarda;Hepatitis C | Drug: Harvoni | Wake Forest University Health Sciences | Gilead Sciences;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH) | Recruiting | 18 Years | N/A | All | 49 | Phase 2 | United States |